Free PSA, PSA Density and PSA Velocity: How Urologists Refine a Borderline Result

The letter from the lab says 5.2, and the line beneath it says only that the value is above the reference range. Nothing else. For the man reading it at his kitchen counter, that single number has to carry the whole weight of a question it was never designed to answer on its own: do I have prostate cancer or not?

Urologists see this letter every week, and they rarely treat the number as a verdict. Instead they reach for a second layer of information. The comparison of free PSA vs total PSA, the calculation of PSA density and the tracking of PSA velocity are three ways of asking the same blood test to say something more useful than yes or no.

None of the three is perfect. Each has a history, a set of cut-offs that were argued over, and honest limitations. Understanding them turns a borderline result from a source of dread into a piece of a picture that is still being assembled.

What PSA actually measures, and why the total number is only half the story

Prostate-specific antigen is a protein made almost entirely by the prostate. Its everyday job is unglamorous: it liquefies semen after ejaculation so that sperm can swim. A small amount leaks into the bloodstream, and that leak is what the PSA blood test picks up, reported in nanograms per milliliter of blood.

Here is the part the lab letter leaves out. PSA does not travel through the blood in one form. Most of it is bound to carrier proteins, chiefly one called alpha-1-antichymotrypsin. A smaller share floats unattached, and that unattached share is what laboratories call free PSA. Total PSA is simply the two added together.

Why does the split matter? Cancerous prostate cells tend to release PSA in a form that binds more readily to those carrier proteins. Benign enlargement, the age-related growth of the gland that most men eventually develop, tends to leak PSA that stays free. The result is that a man whose prostate is large but healthy often has a higher proportion of free PSA than a man whose prostate harbors a tumor, even if their total numbers look identical.

The National Cancer Institute is blunt about the limits of the total number alone: there is no single PSA level that separates cancer from no cancer, and only about one in four men who go on to biopsy because of a raised PSA turn out to have prostate cancer. The other three had a false alarm, most often from benign enlargement or inflammation.

That is the gap the refinements try to close. A urologist who orders a free PSA, calculates a density or looks back at earlier values is not doubting the original test. The goal is to squeeze more meaning from a molecule that, on its own, cannot tell a swollen gland from a sick one.

Free PSA vs total PSA: what the percentage tells a urologist

When a laboratory runs a free PSA test, it reports the result in two ways: the free PSA as a value, and the free PSA as a percentage of the total. It is the percentage that clinicians actually use. The direction is counter-intuitive for many patients, so it bears stating plainly. A higher percentage of free PSA is generally the reassuring result. A lower percentage is the one that raises concern.

Think of it like a glass of cloudy water. Total PSA is how full the glass is. Percent free PSA is how clear the water is. A very full glass of clear water is less worrying than a moderately full glass of murky water.

The test was developed specifically for the so-called grey zone, where the total PSA is elevated but not dramatically so and the prostate feels normal on examination. The landmark multicenter study published in JAMA in 1998 enrolled men in exactly this situation, with total PSA between 4 and 10 and a benign digital rectal examination, and found that the percentage of free PSA sorted them into meaningfully different risk groups.

Outside that zone the test is far less informative. If total PSA is very high, cancer is already likely enough that a percentage rarely changes the plan. If total PSA is well within the normal range, the percentage has not been validated as a reason to act.

One practical point patients seldom hear: free PSA is a fragile molecule. It degrades faster than bound PSA once blood leaves the body, so samples need to be processed promptly. A result from a sample that sat too long can read artificially low, which is one reason a urologist may prefer to repeat a surprising free PSA rather than act on it immediately.

Free PSA ratio normal range: where the 25 percent cut-off came from

Ask a urologist for a normal free PSA ratio and you will usually hear the figure 25 percent. That number is not arbitrary; it comes from the 1998 JAMA trial led by Catalona and colleagues, which remains the study most clinicians have in mind when they interpret the test.

In that study of men with total PSA between 4 and 10 and a normal prostate examination, a free PSA percentage above 25 was associated with roughly an 8 percent chance of cancer on biopsy. A percentage of 10 or below carried a probability of about 56 percent. Between those extremes the risk climbed steadily as the percentage fell. Using 25 percent as the threshold would have detected 95 percent of the cancers in the study while sparing about 20 percent of the men a biopsy they did not need.

Those figures deserve two caveats. First, they describe a specific population: men already in the grey zone with a benign exam, mostly white and mostly in their sixties. The same percentage may carry different meaning in a man of a different age, ethnicity or prostate size. Second, the cut-off was a trade-off, not a law of nature. A lower threshold catches fewer cancers but avoids more biopsies; a higher threshold does the reverse. Different laboratories and guidelines have used values between 10 and 25 percent depending on how they weighed that trade-off.

So there is a range of normal, but it is a range with soft edges. A free PSA of 22 percent is not a failing grade, and 27 percent is not a clean bill of health. It shifts the odds, and a good clinician will tell you in which direction and by roughly how much, then set it beside everything else that is known about you.

Is free PSA more important than total PSA?

The honest answer is that neither is more important; they answer different questions. Total PSA is the screening question: is there anything here worth a closer look? Free PSA is the triage question: given that something is here, how worried should we be?

Free PSA cannot replace total PSA because it only has meaning as a proportion. A free PSA value on its own, without the total to divide it by, tells a clinician nothing. And it was never designed to be a first-line screening test in men with a normal total; the validation studies that established its usefulness all started with men whose total PSA was already raised.

Nor is free PSA the strongest single refinement available. In many practices it has been overtaken by imaging. Guidance from NICE in the United Kingdom now recommends that men with a suspected localised prostate cancer be offered multiparametric MRI before any biopsy, precisely because the scan can show whether a suspicious area exists and where it lies. A blood ratio cannot do that.

Where free PSA still earns its place is in the decision about whether to reach the MRI stage at all, and in men for whom MRI is difficult, for example those with certain implants or severe claustrophobia. It is also inexpensive to add to a blood draw that is already happening, which is why many laboratories run it automatically when the total falls in the grey zone.

Patients sometimes arrive asking for the free PSA as though it were the real test and the total merely a rough draft. It is better understood as a footnote that makes the main text more legible. A footnote can change how you read a sentence, but it cannot stand in for the sentence itself.

PSA density calculation: why prostate size changes what a number means

Two men each have a total PSA of 6. The first has a prostate the size of a walnut, roughly 25 milliliters. The second has a prostate the size of a small orange, closer to 80 milliliters. Should their identical numbers worry a urologist equally? Almost certainly not, and PSA density is the tool that makes the difference visible.

PSA density is total PSA divided by prostate volume in milliliters. The calculation is simple; the hard part is knowing the volume, which comes from imaging. Transrectal ultrasound was the traditional method, and MRI now provides it as a by-product of the scan many men have anyway.

The logic rests on a basic fact of prostate biology. Benign tissue produces PSA, and more benign tissue produces more of it. A large gland can legitimately push the total PSA into the grey zone with no cancer present. Cancer, by contrast, produces disproportionately more PSA per gram of tissue. So a high PSA relative to the size of the gland points toward cancer, while a high PSA that is fully explained by a big gland points toward benign enlargement.

The threshold most often quoted is 0.15 nanograms per milliliter per milliliter. In our two men above, the walnut-sized prostate gives a density of 0.24; the orange-sized prostate gives 0.075. Same PSA, very different pictures.

Density has quietly become one of the more trusted refinements, and it appears in several modern pathways for deciding which men with a reassuring or equivocal MRI can safely avoid biopsy. It has its own weak spots. Volume estimates vary between operators and methods by a meaningful margin, and the 0.15 cut-off, like the 25 percent free PSA cut-off, is a line drawn through a gradient rather than a natural boundary.

What is PSA velocity, and why urologists trust it less than it sounds

PSA velocity is the rate at which total PSA changes over time, usually expressed as nanograms per milliliter per year. The idea has intuitive appeal. A number that jumps from 2 to 5 in eighteen months feels more alarming than a number that has drifted from 4.5 to 5 across a decade, even though the second man has the higher value today.

The historical benchmark was a rise of more than 0.75 nanograms per milliliter per year, drawn from studies in the early 1990s that suggested men with cancer tended to cross that pace while men with benign disease did not. For a time it was written into screening guidance and many patients were biopsied on the strength of it.

Then larger studies looked harder, and the picture blurred. Once a man’s current PSA level and age were taken into account, adding velocity did not improve the prediction of cancer in most analyses. Much of what velocity appeared to capture was simply the fact that a higher PSA today is more concerning, which the current value already tells you. Major urological guidelines on both sides of the Atlantic have since stepped back from using velocity as a stand-alone trigger for biopsy.

That does not make it useless. PSA is noisy; the same man tested twice in a month can vary noticeably because of inflammation, recent ejaculation, laboratory differences or plain biological fluctuation. A single sharp jump is therefore more likely to be noise than signal, and the sensible response is a repeat test rather than a rushed biopsy. A sustained, consistent climb across several readings in the same laboratory is a different matter and is one of the reasons clinicians like to see a series of values rather than one.

Velocity, in other words, is context rather than a criterion.

Who these refinements are usually for, and who is usually asked to wait

The refinements were built for a specific man: one whose total PSA is raised but not dramatically, whose prostate examination is unremarkable or shows only smooth enlargement, and for whom the next step, an MRI or a biopsy, carries genuine downsides. In that situation, free PSA, density and a look back at earlier values can each nudge the decision one way or the other.

Several other groups also benefit. Men already on active surveillance for a low-grade cancer, where the question is whether the disease is changing rather than whether it exists, often have density and serial values tracked closely. Men with a large benign gland whose PSA sits stubbornly above the reference range year after year are natural candidates for density, since it can explain the number without repeated invasive testing. Men for whom MRI is impractical lean more heavily on blood-based refinements.

Then there are the men who are usually asked to wait, or for whom the tests are not the right tool. A man with a PSA comfortably in the normal range and no symptoms is generally not offered free PSA, because the test has not been validated to change management there; the CDC notes that routine screening discussions are mainly relevant between ages 55 and 69, with individual decisions outside that window. A man whose PSA is very high or whose examination reveals a hard nodule is usually moved directly to imaging or referral, since a ratio would not alter the urgency.

Finally, timing matters. A man who has had a urinary infection in the past six weeks, a prostate biopsy recently, or ejaculation or vigorous exercise within the past two days may simply be asked to come back, because the NHS guidance on PSA testing lists each of these as reasons a result can be temporarily misleading. Waiting a few weeks is not neglect; it is quality control.

The three refinements side by side

Patients often meet all three terms in the same appointment, and the differences blur. The table sets them out in the form clinicians actually use.

Refinement	What it needs	Direction that raises concern	Common reference point	Main strength	Main limitation
Percent free PSA	One blood sample, promptly processed	Lower percentage	Below about 25 percent (some use 10 to 20)	Cheap add-on; well studied in the 4 to 10 grey zone	Unstable molecule; little value outside the grey zone
PSA density	Total PSA plus prostate volume from ultrasound or MRI	Higher density	Above about 0.15 ng/mL per mL	Explains high PSA from a large benign gland; used in modern MRI pathways	Volume estimates vary between operators
PSA velocity	At least three readings over 18 to 24 months, ideally same lab	Faster sustained rise	Historically above 0.75 ng/mL per year	Flags change in men followed over time	Adds little once current PSA and age are known; noisy

A few observations fall out of the table. Free PSA and density answer a question about a snapshot; velocity answers a question about a film. Density is the only one that requires imaging, which is why it has grown in importance as MRI before biopsy has become standard practice. And each has a reference point that is a convention rather than a threshold in nature, which is why a urologist will speak of a result being reassuring or concerning rather than normal or abnormal.

None of them is scored in isolation. Increasingly they are fed, along with age, family history, ethnicity and examination findings, into risk calculators that produce an estimated probability of a clinically significant cancer. The refinements are ingredients, not the meal.

What can raise a PSA that has nothing to do with cancer

Before anyone calculates a ratio or a density, a good clinician asks a simpler question: was this PSA measured under fair conditions? A surprising number of borderline results turn out to be artifacts of timing.

Ejaculation releases PSA into the bloodstream, and the NHS advises men to avoid it for 48 hours before a test. Vigorous exercise, especially cycling, can do the same because the saddle presses directly on the gland; the same 48-hour window applies. A urinary tract infection or prostatitis, which is inflammation of the prostate, can push PSA up several-fold and keep it there for weeks, which is why a test is generally deferred for six weeks after an infection. A recent prostate biopsy or catheter can have a similar effect.

Benign prostatic enlargement is the most common non-cancer cause of a raised PSA and the one PSA density was invented to account for. Its effect is not temporary, so repeating the test does not help; interpreting it in the light of gland size does.

Medicines matter too. The class known as 5-alpha-reductase inhibitors, used to shrink an enlarged prostate, roughly halves PSA after about six months of use, a fact noted in the NCI’s PSA fact sheet. A man taking one of these medicines whose PSA reads 3 may in effect have a PSA of 6, and laboratories and clinicians adjust for this. Anyone in this situation should make sure the ordering clinician knows about the prescription; the medicine itself should not be started, paused or changed on account of a PSA result without the prescriber’s guidance.

A digital rectal examination causes only a small, brief rise and is not generally considered a reason to delay the blood draw, though some clinicians prefer to take blood first. Anal intercourse and some urological procedures can also raise the value. The through-line is simple: a borderline number is a number worth repeating under clean conditions before anyone builds a decision on it.

What a normal free PSA looks like for a 70-year-old, and how age shapes the picture

The question arrives in almost these words, and the answer has two parts. The percent free PSA cut-off does not meaningfully change with age; 25 percent is still the figure clinicians have in mind at 70 as at 55. What does change is the total PSA against which the percentage is judged, and the wider question of what a positive result would lead to.

Total PSA rises with age because the prostate grows. Older studies proposed age-specific reference ranges, with an upper limit for men in their seventies noticeably higher than for men in their fifties. UK practice reflects this: the NHS PSA testing guidance uses a referral threshold of 3 nanograms per milliliter for men aged 50 to 69 and a higher threshold of 5 for men aged 70 and over. In the United States there is no single national threshold, and the NCI stresses that there is no universally agreed normal.

So a 70-year-old with a total PSA of 4.5 and a free PSA of 28 percent is, by most yardsticks, in reassuring territory on both counts. The same man with a free PSA of 12 percent has a result that would prompt discussion, though the discussion at 70 differs from the discussion at 55.

That difference is the second part of the answer. Prostate cancer detected at 70 is frequently slow-growing, and the benefit of finding it depends heavily on a man’s other health and expected lifespan. The CDC observes that routine screening is generally not recommended for men aged 70 and older because the harms, chiefly overdiagnosis and treatment side effects, tend to outweigh the benefits at a population level. For an individual man, that calculus is personal, and it belongs in a conversation with his own clinician rather than in a table of reference ranges.

Age does not change what free PSA means. It changes what one is prepared to do about it.

What the following weeks usually look like after a borderline result

The path from a borderline PSA to a decision is rarely a sprint, and knowing the typical sequence takes some of the anxiety out of the waiting.

The first step, in most practices, is a repeat total PSA under clean conditions: no ejaculation or heavy exercise for two days beforehand, no recent infection, and ideally the same laboratory. Mayo Clinic and others note that a meaningful proportion of borderline values fall back into range on repeat, ending the episode there. This retest is usually scheduled a few weeks after the first, long enough for any transient cause to settle.

If the repeat confirms the elevation, the free PSA percentage is often run on the same sample, and the clinician performs or reviews a digital rectal examination. A history is taken: family members with prostate or breast cancer, urinary symptoms, medicines that alter PSA, ethnicity, and prior values that allow a rough sense of trajectory.

The next branch is imaging. Under NICE guidance a man whose overall picture suggests a possible localised cancer is offered multiparametric MRI before any biopsy. The scan takes about half an hour, and it does two things at once: it looks for suspicious areas and it measures the gland, which yields the PSA density. Men whose scan is reassuring and whose density is low are increasingly offered the option of monitoring rather than biopsy; men with a suspicious lesion are offered a biopsy targeted to it.

Biopsy, if it comes, is a same-day procedure, and results typically return within a couple of weeks. The whole sequence, from first borderline value to a clear plan, commonly spans several weeks to a few months. That pace is deliberate, not sluggish; it exists to avoid treating men who never needed treatment, and every step along the way is a decision shared with the treating team rather than imposed by a number.

What people often get wrong about free PSA vs total PSA

The first misunderstanding is directional. Many men assume that more free PSA must be worse, because more of anything on a cancer test sounds bad. The reverse is true: a higher percentage of free PSA leans toward benign disease. Getting this backwards has caused real distress in kitchens and waiting rooms.

The second is treating the 25 percent line as a diagnosis. A free PSA of 18 percent does not mean a man has cancer; in the JAMA trial that established the test, most men in the middle range did not. Equally, 30 percent does not rule cancer out. The study’s own figures put the risk above 25 percent at around 8 percent, low but not zero. The test moves probabilities. It does not deliver certainties.

Third is the belief that free PSA is a better screening test that should replace the ordinary PSA. It has not been validated for that role. Its evidence base sits almost entirely in men whose total was already raised.

Fourth is faith in velocity. A single jump between two readings is far more often laboratory variation or a passing inflammation than a tumor announcing itself. Guidelines have retreated from using velocity as a trigger for biopsy for exactly this reason.

Fifth is the idea that a high PSA density proves cancer or a low one excludes it. Density is powerful precisely because it puts PSA in proportion to gland size, but the volume measurement carries its own error, and the 0.15 cut-off is a convention.

The last and most consequential myth is that finding cancer is always better than not finding it. The CDC and NCI both emphasize that many prostate cancers detected through PSA would never have caused harm, and that treating them carries risks of urinary and sexual side effects. The refinements exist as much to protect men from unnecessary biopsies and treatment as to catch disease. Both aims are legitimate, and a borderline result is where they meet.

Questions to ask your care team about a borderline PSA

A consultation about a borderline PSA moves fast and uses unfamiliar words. Arriving with questions written down makes it easier to leave with answers you actually understand. These are the ones that tend to unlock the most useful conversations.

• Was my PSA taken under conditions that could have raised it, and should it be repeated before we do anything else?
• What is my percent free PSA, and how does that shift my likelihood of a significant cancer compared with the total PSA alone?
• Do we know my prostate volume, and what does my PSA density work out to?
• How many previous PSA values do I have, and do they show a stable pattern or a sustained rise?
• Am I taking any medicine that lowers PSA, and has that been accounted for in reading my result?
• Would an MRI change what we do next, and is it the recommended next step in my case?
• If the MRI is reassuring, is monitoring without a biopsy an option for me?
• What would a biopsy involve, what are its risks, and what are the alternatives to having one now?
• Given my age and overall health, how would finding a slow-growing cancer change my life, and is that a trade-off I want to make?
• When and how will we review this again, and what result would prompt us to act sooner?

Two habits help. Ask the clinician to say the number aloud and to say which direction is reassuring, since the direction is the part most often misremembered. And ask for the plan in one sentence before you leave: repeat in six weeks, MRI next month, or monitoring with a date. A borderline PSA is a reason for a plan, and the plan is something you and your treating team build together.

When to call your doctor

Most of what surrounds a borderline PSA unfolds at the measured pace of scheduled tests and appointments, and that pace is appropriate. Some situations, though, should not wait for the next planned review.

Contact your doctor promptly if you develop a fever or chills with pain in the lower back, pelvis or perineum, especially with burning or difficulty passing urine; this can indicate a prostate or urinary infection that needs assessment and will also make any PSA result unreliable until it has settled. Seek care the same day if you cannot pass urine at all, if you see visible blood in your urine or semen that does not clear within a day or two, or if you have new, persistent pain in the bones, hips or back that is not explained by activity.

After a prostate biopsy, call if you have a temperature, shaking, heavy or prolonged bleeding, or inability to urinate, since infection and retention are recognized complications that are treatable when caught early.

Less urgent but still worth a call: a PSA result you do not understand, a new prescription for a medicine that affects PSA, a family member newly diagnosed with prostate or breast cancer, or worsening urinary symptoms between scheduled reviews. None of these is an emergency, but each is information your treating team would want before the next decision.

The refinements described in this article, free PSA, density and velocity, are tools for interpreting a number, not substitutes for a conversation. Every decision about repeating a test, having a scan, proceeding to biopsy or choosing monitoring rests with you and the clinicians who know your full history. A borderline result is a question, and the right person to help answer it is the one who ordered the test.

Frequently asked questions

Is free PSA more important than total PSA?

Neither is more important; they do different jobs. Total PSA identifies whether a closer look is warranted, while percent free PSA helps estimate how likely cancer is once the total is already in the borderline range. Free PSA has no meaning without the total to divide it by, and it has not been validated as a first-line screening test in men whose total PSA is normal.

What is a normal ratio of free PSA to total PSA?

A percent free PSA above about 25 percent is generally considered reassuring, based on the 1998 JAMA multicenter trial. Values between 10 and 25 percent carry rising concern as they fall, and 10 percent or below is associated with a substantially higher likelihood of cancer. These are conventions drawn through a gradient, so a result just under 25 is not a diagnosis, only a shift in probability.

Is free PSA a predictor of prostate cancer?

It is a predictor of probability, not a detector of disease. In men with total PSA between 4 and 10 and a normal examination, a lower percent free PSA is associated with a higher chance that a biopsy will find cancer. It cannot show where a tumor is or how aggressive it might be, which is why an MRI and, if needed, a biopsy remain the steps that actually establish a diagnosis.

What is a normal free PSA for a 70 year old?

The percent free PSA reference point does not change with age; about 25 percent remains the reassuring threshold at 70. What changes is the total PSA it is judged against, which rises naturally with a larger gland; NHS guidance, for example, uses a higher referral threshold for men aged 70 and over than for men aged 50 to 69. Whether to act on any result at 70 depends on overall health and personal preference.

How is percent free PSA calculated?

The laboratory measures free PSA and total PSA on the same blood sample, divides free by total and multiplies by 100. A free PSA of 1.2 with a total of 6.0 gives 20 percent. Because free PSA degrades faster than bound PSA once blood is drawn, the sample must be processed promptly, and an unexpectedly low percentage is sometimes repeated to rule out a handling artifact.

Can free PSA be tested if my total PSA is under 4?

It can be measured, but it is unlikely to be helpful. The studies that established the test enrolled men whose total PSA was already between 4 and 10 with a normal examination. Below that range the percentage has not been shown to change management, and most clinicians would rely instead on the total value, age, family history and, where relevant, prostate volume.

Does a high free PSA percentage mean I definitely do not have cancer?

No. In the JAMA trial, men with free PSA above 25 percent still had a cancer probability of roughly 8 percent on biopsy. A high percentage lowers the likelihood and often supports monitoring rather than immediate biopsy, but it does not exclude cancer. A clinician will weigh it alongside your examination, any prior values, gland size and, where appropriate, an MRI.

How is PSA density calculated if I have not had an MRI?

Density needs a prostate volume, which can also come from transrectal ultrasound, the traditional method. The clinician divides total PSA by volume in milliliters; a PSA of 6 with a 40 milliliter gland gives 0.15. Without any imaging, density cannot be calculated, and the digital rectal examination offers only a rough impression of size. MRI is increasingly the source because it provides volume and images at the same time.

Does a rising PSA always mean cancer?

No. PSA fluctuates from infection, inflammation, recent ejaculation, exercise and ordinary laboratory variation, so a single jump between two readings is more often noise than signal. Larger studies found that velocity adds little once current PSA and age are known, and guidelines no longer use a fast rise on its own as a trigger for biopsy. A sustained climb across several readings in the same laboratory is more meaningful.

Why did my doctor ask me to repeat the PSA before ordering free PSA?

Because many borderline results fall back into range on repeat, ending the question before any further test is needed. A second measurement under clean conditions, with no ejaculation or heavy exercise for two days and no recent infection, confirms whether the elevation is real. Running free PSA on a value that may itself be an artifact would simply refine a number that should not have been trusted.

References

• PSA testing – Prostate cancer – NHS
• Prostate-Specific Antigen (PSA) Test – MedlinePlus
• Screening for Prostate Cancer – CDC

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.